ExploreWatchlistsPricing
  1. JP-listed companies
  2. Renascience Inc.
  3. Financials
  4. Retained earnings

Renascience Inc. (4889)

Market cap
¥20.6B
P/E ratio
-59.7x
Rena Science develops pharmaceuticals, medical devices, and AI-powered software to address critical health challenges including cancer, diabetes, and age-related diseases.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRetained earnings (Million JPY)YoY (%)
Mar 31, 2025-835-11.96%
Mar 31, 2024-948+37.43%
Mar 31, 2023-690+94.77%
Mar 31, 2022-354+254.15%
Mar 31, 2021-100-72.59%
Mar 31, 2020-365

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat